Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose colchicine added to standard care in type 2 diabetes patients with acute myocardial infarction
ChiCTR1800017471Phase 3Not yet recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Sep 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in myocardial infarction (MI) and type 2 diabetes mellitus (T2DM) comparing Low-dose colchicine group with Placebo control group (2 arms). Primary endpoint: Major cardiovascular events. Planned start Sep 2018; status: not yet recruiting.
02
Drugs
colchicine
03
Conditions
myocardial infarction (MI)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR1800017471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017471.